REGNASE-1 Gene Knockout or BATF Overexpression for Improving T-cell Function (SJ-19-0027, SJ-20-0007)

St. Jude Reference #SJ-19-0027, SJ-20-0007


In patients, poor persistence and function of adoptively transferred cells are major obstacles for T cell-based tumor therapies. St. Jude researchers demonstrated that by knocking out REGNASE-1, which is identified in an in vivo CRISPR discovery platform, CD8 T cell long-term persistence is greatly improved (up to 2000x), and these cells are resistant to functional exhaustion and retain robust effector function. Strikingly, REGNASE-1 deficient CD8 T cells have greatly improved ability in controlling both solid and blood cancers; making it useful in engineered T cell, including CAR-T cell, based tumor immune therapy, and potentially, regulatory T cell (Treg) based immune therapy in autoimmune diseases. Additional factors were identified to act alone or in combination with REGNASE-1 deletion to improve T-cell function.

The researchers also discovered that by overexpressing one single molecular (BATF; Basic Leucine Zipper ATF-Like Transcription Factor), the accumulation and effector function of tumor-specific T cells are markedly enhanced. This is useful for immunotherapy against solid and blood cancers using CAR-T and other engineered T cells.


adoptive T cell cancer therapy, CAR-T, REGNASE-1, Basic Leucine Zipper ATF-Like Transcription Factor (BATF), long-term persistence, effector function, solid tumor, blood cancer, autoimmune diseases, CRISPR

Granted Patents or Published Applications

Related Scientific References

The paper is online now.

It is also selected by News and Views in Nature

News media: and

A broader background article:

Licensing Opportunities

More information is available under a confidentiality agreement. Contact

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.